Rotavirus Vaccine Administration in Preterm and Medically Fragile Infants Admitted to Neonatal Intensive Care Units: Second Phase Enrollments and Final Results of a Multicenter Observational Study Conducted in Sicily, Italy
Related Experiment Video
Updated: Jun 13, 2026

Efficient Recombinant Parvovirus Production with the Help of Adenovirus-derived Systems
Published on: April 23, 2012
Claudio Costantino1, Nicole Bonaccorso1,2, Walter Mazzucco1
1Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Excellence Specialties (PROMISE) "G. D'Alessandro", University of Palermo, 90127 Palermo, Italy.
Insights
Rotavirus vaccination is safe for premature infants. This study found no adverse events in preterm infants receiving the rotavirus vaccine in Sicilian Neonatal Intensive Care Units, supporting its continued use.
Area of Science:
- Neonatalogy
- Pediatric Infectious Diseases
- Vaccinology
Background:
- Rotavirus disease is a leading cause of severe gastroenteritis and mortality in children under five.
- Premature infants are at higher risk for rotavirus gastroenteritis (RVGE) and its complications.
- International health authorities recommend rotavirus vaccination due to its proven efficacy in reducing disease burden and costs.
Purpose of the Study:
- To evaluate the safety of anti-rotavirus vaccination in premature infants.
- To assess vaccination outcomes in Neonatal Intensive Care Units (NICUs) during the pandemic.
- To provide data supporting public health strategies for vulnerable infant populations.
Main Methods:
- Administered the monovalent rotavirus vaccine (RV1) to preterm infants (gestational age ≥28 weeks) in Sicilian NICUs from January 2020 to December 2022.
- Vaccinated both hospitalized infants and those attending post-discharge follow-up, starting at six weeks of age.
- Monitored all potential adverse events (expected, unexpected, serious) for 28 days post-vaccination for both doses.
Main Results:
- 355 preterm infants (mean gestational age 33.2 weeks) completed the vaccination schedule.
- Vaccination occurred at a mean age of 7 weeks with a mean weight of 3439g.
- No expected, unexpected, or serious adverse events were recorded within 14 or 28 days after either vaccine dose.
Conclusions:
- Rotavirus vaccination is confirmed as safe for preterm infants born at or after 28 weeks of gestational age.
- Continued in-hospital vaccination strategies are crucial, especially during periods of reduced vaccine adherence.
- Multidisciplinary collaboration between neonatologists and pediatricians is vital for promoting vaccination in fragile infant populations.
Abstract:
Rotavirus disease is the world's leading cause of severe gastroenteritis and mortality in children up to 5 years of age. Premature infants are more vulnerable to rotavirus gastroenteritis (RVGE) and its complications. International authorities strongly recommend vaccination because of the consistent reduction in infections, hospitalizations, deaths, and related costs.
Background/Objectives:
The objective of the present study was to evaluate the safety of anti-rotavirus vaccination in premature infants admitted and vaccinated in the main Sicilian Neonatal Intensive Care Units (NICUs) during the pandemic period.
Methods:
The human monovalent rotavirus vaccination (RV1) was administered to preterm infants of gestational age ≥28 weeks in the main Sicilian NICUs from January 2020 to December 2022, as a prolongation of a similar study conducted from April 2018 to December 2019. Rotavirus vaccinations were provided both to hospitalized infants and to those returning for post-discharge follow-up, beginning at six weeks of age according to the official immunization schedule. All potential adverse events-whether expected, unexpected, or serious-were recorded from the day of vaccination through 14 days (first follow-up) and 28 days (second follow-up) after each of the two scheduled doses.
Results:
A total of 355 preterm infants were fully vaccinated with RV in four Sicilian NICUs. The mean gestational age of newborns was 33.2 weeks (±2.7), 53% of whom were male. Vaccination was performed on average at 7 weeks of age (±2.1), and the mean weight at the time of vaccination was 3439 g (SD ± 745.2). No expected/unexpected or serious adverse events were observed either within the 14-day or within the 28-day period after administration of both two doses.
Conclusions:
Data confirm that vaccination in preterm infants ≥28 weeks gestational age is safe. The prolongation of this Public Health strategy, strongly recommended by the Sicilian Health Department during the pandemic period that also generally has led to a reduction of vaccination adherence and acceptance of pediatric vaccination, demonstrates the importance of multidisciplinary collaboration with neonatologists and pediatricians to continue promoting in-hospital vaccinations for fragile subjects.
Related Concept Videos
Bacterial Gastroenteritis
Poliomyelitis
Respiratory Syncytial Virus Disease

